New Treatment Options for Methicillin-Resistant Staphylococcus Aureus

Since late May, the Food and Drug Administration (FDA) has approved two new drugs - Dalvance and Sivextro - to treat acute bacterial skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and certain other bacteria. These drugs were the first to be approved under a new Qualified Infectious Disease Product program that includes incentives to entice pharmaceutical companies to develop drugs to help fight antibiotic resistance. Dalvance is administered intravenously and Sivextro is available for intravenous and oral use. FDA news releases on these drugs are available at: